BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Patrys Limited (PAB.AX) Granted Key Patent for Lead Product – PAT-LM1


6/7/2013 9:21:46 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Melbourne, Australia; 6 June, 2013: Patrys Limited (ASX: PAB), a clinical stage biopharmaceutical company is pleased to advise that it has been granted a New Zealand patent for lead anti-cancer product PAT-LM1.

The New Zealand Patent Office has issued a certificate of grant on a key patent in the PAT-LM1 family, PCT/IB2009/007082 entitled “LM-antibodies, functional fragments, LM-1 target antigen, and methods for making and using same”. This is the second jurisdiction in which the PAT-LM1 patent has been granted.

“New Zealand is a major market in the Australasian region, and it is very pleasing to add this patent to Patrys’ already extensive portfolio, which includes patents in other key jurisdictions”, said Dr. Marie Roskrow, Patrys’ Chief Executive Officer.

The patent, which is owned by Patrys, claims the use of the antibody PAT-LM1 that binds to its target Nmt55/NONO for the treatment or prevention of metastasis.

PAT-LM1 is currently under preclinical development.

For further information, please contact:

Patrys Limited:

Dr. Marie Roskrow

Chief Executive Officer

P: +61 3 9670 3273

info@patrys.com

Patrys IR:

Rebecca Wilson

Buchan Consulting

P: 0417 382 391

rwilson@buchanwe.com.au

Patrys Media:

Shevaun Cooper

Buchan Consulting

P: +61 3 9866 4722

scooper@buchanwe.com.au

About Patrys Limited:

Based in Melbourne, Australia, Patrys (ASX: PAB) is focused on the development of natural human antibodies as therapies for cancer and other major diseases. Patrys has a deep pipeline of anti-cancer natural human antibodies that enable both internal development and partnering opportunities. More information can be found at www.patrys.com.


Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->